Genetic susceptibility to behavioural and psychological symptoms in alzheimer disease

Current Alzheimer Research

Volumn 7, Issue 2, 2010, Pages 158-164

  Borroni, B ^a   Costanzi, C ^a   Padovani, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; NEUROTROPHIN; SEROTONIN;

ALZHEIMER DISEASE; BEHAVIOR; DEMENTIA; DEPRESSION; DISEASE PREDISPOSITION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYMPTOM;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; GENETIC PREDISPOSITION TO DISEASE; MICE; NERVE GROWTH FACTORS; NEURAL PATHWAYS; POLYMORPHISM, GENETIC;

EID: 77949690062     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790691173     Document Type: Review

References (80)

1. REFERENCES [1] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944 (1984).
2. Mesulam MM, Mefsun EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214: 170-197 (1983).
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (III-R ed.). American Psychiatric Press: Washington, DC (1987).
4. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47: 876-883 (1996).
5. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147 (1999).
6. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46: 130-135 (1996).
7. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, et al. Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 84: 125-140 (1988).
8. Lee MM, Strauss ME, Dawson DV. Changes in emotional and behavioral symptoms of Alzheimer's disease. Am J Alzheimer Dis Other Demen 15: 176-179 (2000).
9. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314 (1994).
10. Finkel SI, Costa E, Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8 (Suppl 3): 497-500 (1996).
11. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 15(Suppl. 1): S2-S4 (2000).
12. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 33: 714-720 (1993).
13. Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 153: 243-247 (1996).
14. Lyketsos CG, Steele C, Steinberg M, Neuropsychiatric symptoms in dementia. In: Care of the Elderly: Clinical Aspects of Aging. 5th ed. (Eds: Gallo JJ, Busby-Whitehead J and Rabins PV). Williams & Wilkins, Baltomore, pp. 214-228 (1999).
15. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. III: disorders of mood. Br J Psychiatry 157: 81-86 (1990).
16. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 15(4): 445-450 (2002).
17. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 15: 365-375 (1999).
18. Moran M, Walsh C, Lynch A, Coen RF, Coakley D, Lawlor BA. Syndromes of behavioral and psychological symptoms in mild Alzheimer's disease. Int J Geriatr Psychiatry 19: 359-364 (2004).
19. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviours in dementia. A review, summary, and critique. Am J Geriatr Psychiatry 9: 361-381 (2001).
20. Levinson DF. The genetics of depression: a review. Biol Psychiatry 60(2): 84-92 (2006).
21. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 28 (suppl 1): S96-S107 (2001).
22. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, et al. Neurochemical studies of early-onset Alzheimer's disease: possible influence on treatment. N Engl J Med 313: 7-11 (1985).
23. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43: 442-449 (2005).
24. Herrmann N, Lanctôt KL. From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can J Psychiatry 42: 51S-64S (1997).
25. Parnetti L, Amici S, Lanari A, Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev 122: 2063-2069 (2001).
26. Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, et al. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: A clinicopathological correlation. Acta Neuropathol 84: 638-650 (1992).
27. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 66: 1592-1598 (1996).
28. Lancot KL, Herrman N, Mazzotta P. Role of serotonin in behavioural and psychological symptoms of dementia. J Neuropsychiatr Clin Neurosci 13: 5-21 (2001).
29. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 45: 1182-1186 (1988).
30. Murphy DL, Andrews AM, Wichems CH, Li Q, Tohda M, Greenberg B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 59(suppl 15): 4-12 (1998).
31. Micheli D, Bonvicini C, Rocchi A, Ceravolo R, Mancuso M, Tognoni G, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis 10(4): 371-8 (2006).
32. Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, et al. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging 29(3): 341-7 (2008).
33. Liu HC, Hong CJ, Liu CY, Lin KN, Tsai SJ, Liu TY, et al. Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease. Psychiatr Clin Neurosci 55(4): 427-9 (2001).
34. Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet 119B(1): 40-3 (2003).
35. Grünblatt E, Zehetmayer S, Bartl J, Löffler C, Wichart I, Rainer MK, et al. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res 43(3): 298-308 (2009).
36. McCulley MC, Day IN, Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 124B (1): 50-3 (2004).
37. Arancio O, Chao MV. Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol 17(3): 325-30 (2007).
38. Schindowski K, Belarbi K, Buée L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7 (Suppl 1): 43-56 (2008).
39. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatr Res 109 (2): 143-8 (2002).
40. Borroni B, Archetti S, Costanzi C, Grassi M, Ferrari M, Radeghieri A, et al. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 30(9): 1406-1412 (2009).
41. López-León S, Janssens AC, González-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 13(8): 772-85 (2008).
42. Delano-Wood L, Houston WS, Emond JA, Marchant NL, Salmon DP, Jeste DV, et al. APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study. Int J Geriatr Psychiatry 23(6): 632-6 (2008). [43] Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 19(2-3): 154-7 (2005).
43. Liu CY, Hong CJ, Liu TY, Lin KN, Wang PN, Chi CW, et al. Lack of association between the apolipoprotein E genotype and depression in Alzheimer's disease. J Geriatr Psychiatr Neurol 15(1): 20-3 (2002).
44. Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J Neurol Neurosurg Psychiatry 78(2): 123-6 (2007).
45. Ballard C, Bannister C, Graham C, Oyebode F, Wilcock G. Associations of psychotic symptoms in dementia sufferers. Br J Psychiatry 167: 537-540 (1995).
46. Cook SE, Miyahara S, Bacanu SA, Perez-Madrinan G, Lopez OL, Kaufer DI, et al. Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatry 11: 406-413 (2003).
47. Cummings JL. Psychosis in neurologic disease. Neurobiology and pathogenesis. Neuropsychiatr Neuropsychol Behav Neurol 5: 144-150 (1992).
48. Förstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 165: 53-59 (1994).
49. Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R. SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry 152: 1470-1475 (1995).
50. Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology 32 (1): 171-9 (2007).
51. Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. Am J Geriatr Psychiatry 7(2): 119-23 (1999).
52. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur J Neurol 13(2): 176-82 (2006).
53. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71: 274-280 (1998).
54. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67: 53-83 (2002).
55. Storga D, Vrecko K, Birkmayer JG, Reinnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 203: 29-32 (1996).
56. Torda C. Effects of catecholamines on behavior. J Neurosci Res 2: 193-202 (1976).
57. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23: 2008-2013 (2003).
58. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 160(3): 469-476 (2003).
59. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol Omethyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 161(2): 359-361 (2004).
60. Borroni B, Agosti C, Archetti S, Costanzi C, Bonomi S, Ghianda D, et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease. Nerosci Lett 370: 127-129 (2004).
61. Sweet RA, Devlin B, Pollock BG, Sukonick DL, Kastango KB, Bacanu SA, et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 10 (11): 1026-36 (2005).
62. Borroni B, Grassi M, Costanzi C, Zanetti M, Archetti S, Franzoni S, et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging 28(8): 1231-8 (2007).
63. Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett 368(1): 33-6 (2004).
64. Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 71(6): 777-9 (2001).
65. Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, et al. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 50(6): 472-5 (2001).
66. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, et al. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test 7(4): 309-14 (2003).
67. Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet 144B(8): 1054-62 (2007).
68. Craig D, Donnelly C, Hart D, Carson R, Passmore P. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 144B(1): 126-8 (2007).
69. Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behaviour in Alzheimer disease. Int Psychogeriatry 13: 401-409 (2001).
70. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 61: 1249-1253 (2004).
71. Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR*S/*L polymorphism and aggressive behaviour in Alzheimer disease. Arch Neurol 58: 1425-1428 (2001).
72. Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry 7: 95-99 (2002).
73. Quaranta D, Bizzarro A, Marra C, Vita MG, Seripa D, Pilotto A, et al. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis 16(1): 173-80 (2009).
74. Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease. J Alzheimers Dis 12(3): 245-53 (2007).
75. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord 24(3): 201-6 (2007).
76. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol 56(1): 121-4 (2004).
77. Carson R, Craig D, Hart D, Todd S, McGuinness B, Johnston JA, et al. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular 10(4): 377-84 (2008).
78. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16: 1043-1053 (2001).
79. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157: 708-714 (2000).
80. Borroni B, Grassi M, Agosti C, Costanzi C, Archetti S, Franzoni S, et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging 27(11): 1595-603 (2006).